02/13/24 "JAK" of All Trades, Master of Atopic Dermatitis?

Dr. James Song, MD, FAAD
Frontier Dermatology
PRESENTATION TITLE:
JAK of all trades, Master of Atopic Dermatitis
PRESENTATION OBJECTIVES:
1. Recognize when one should consider the use of JAK inhibitors in treating atopic dermatitis
2. Appraise safety data for JAK inhibitors and discuss what this means in the context of dermatology
3. Discuss best practices for risk mitigation and improving patient adherence
DISCLOSURES:
• AbbVie (C,S,I)
• Amgen (C,S,I)
• Arcutis (C,S,I)
• BMS (C,S,I)
• Boehringer Ingeheim (C)
• Dermavant (C,S)
• Eli Lilly (C,S)
• Incyte (C,S,I)
• Janssen (C,S,I)
• LEO (C)
• Novartis (C,S)
• Ortho-dermatologics (C,S)
• Pfizer (C,S)
• Sanofi & Regeneron (C,S)
• SUN (C,S,I)
• UCB (C,S)
C: Consultant
S: Promotional Speaker
I: Clinical Investigator

[@Cygx]

Basically the danger profile of Rinvoq (upadacitinib) and Cibinqo (abrocitinib) safety profile shouldn't be as severe as the black box warning because is it more selective and that it is possible for 20% of patients to be fully clear without the need of restarting the drug 25:02